Global Diabetes Drugs Market: Snapshot
The global diabetes drugs market is predicted to display steadfast growth in the near future. Increasing incidence of diabetes due to sedentary lifestyle coupled with consumption of high calorie food stokes demand for therapeutics for diabetes. Growing geriatric population globally susceptible to age-related medical conditions such as diabetes and blood pressure is also boosting the diabetes drugs market.
Diabetes is a chronic medical condition wherein insulin is produced in insufficient amount, or if insulin is produced but is not absorbed by the body.
Research and development initiatives for the introduction of improved drugs is also accentuating the growth of diabetes drugs market.
As per a report by Transparency Market Research (TMR), the global diabetes drugs market is predicted to clock a CAGR of 3.6% over the forecast period between 2017 and 2025. At this pace, the market’s valuation of US$43.1 bn in 2016 will become US$58.4 bn by the end of 2025.
Hospital Pharmacies to Remain Key Distribution Segment
The global diabetes drugs market is segmented in terms of disease type, therapy type, distribution channel, and region. By therapy type, the diabetes drugs market is classified into sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, insulin, and others. By distribution channel, the diabetes drugs market has been segregated into hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies, among them, accounts for the leading market share due to availability of trained staff to sell medicines. Online pharmacies are anticipated to hold significant share in the near future due to proliferation of e-commerce and rising popularity of e-tail.
Growth of Type 2 Diabetes Disease Type Segment to Remain at Fore
Depending upon disease type, the diabetes drugs market is segmented into type1 diabetes, type 2 diabetes, impaired glucose tolerance, gestational diabetes, and impaired fasting glycaemia. Out of these, type 2 diabetes holds a leading share in the overall market due to its higher prevalence. Rapid rate of growth of obesity in the urban population, improving healthcare facilities, and rising disposable income are serving to boost the growth of type 2 diabetes segment. Meanwhile, type 1 diabetes accounts for second-leading share of the market. Gestational diabetes, impaired fasting glycaemia, and impaired glucose tolerance segments are projected to rise at a steady pace over the forecast period.
Geographically, the diabetes drugs market has been segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America, among them, held the leading share of the market in 2016 due to high prevalence of diabetes. Europe held the second-leading share of the market in 2016 due to an established research and development infrastructure for drug improvement.
The Middle East & Africa is anticipated to emerge as a key market for diabetes drugs due to increasing prevalence of diabetes and rising disposable income in the region.
Some of the top companies operating in the global diabetes drugs market are Novo Nordisk A/S, Boehringer Ingelheim GmbH, Novartis AG, Bayer AG, Merck & Co., and Sanofi. Some other prominent companies operating in this market are Takeda Pharmaceutical Company Limited, Johnson & Johnson, Boehringer Ingelheim GmbH, and Eli Lily and Company.
Global Diabetes Drugs Market: Snapshot
This report on the Diabetes drugs market analyzes the current and future scenario of the global market. Rise in private and public funding for diabetes drugs, rising prevalence of diabetes, and favorable regulatory scenario for new drug launch are boosting the growth of the Diabetes drugs market. Increasing geriatric population across the world and rising incidence and prevalence of diabetes such as Type 2 diabetes and Type 1 diabetes are some of the factors expected to drive the growth of Diabetes drugs market during the forecast period.
The diabetes drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on therapy, disease type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints, opportunities and trends have been provided in the market overview section. Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Diabetes drugs market.
Global Diabetes Drugs Market: Segmentation
Based on the therapy, the Diabetes drugs market has been segmented into 5 types, which are Glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin and others. . The insulin dominated the market in terms of revenue in 2016, due to its high price, and need & demand for insulin. Insulin is expected to lead the market in the forecast period, owing to the rising geriatric population and high per capita income. SGLT2 is anticipated to grow during the forecast period owing to patents and exclusivity held for the drugs of this segment by the key players. The others segment includes the combination drugs and other drug classes are anticipated to grow during the forecast period 2017 to 2025. The Glucagon-like peptide-1 (GLP-1) agonist is anticipated to grow during the forecast period owing to rising prevalence of diabetes all over the world.Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share in 2016, however, the segment is anticipated to fall in the growth rate during the forecast period due to patent and exclusivity expiry.
In terms of disease type, the diabetes drugs market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. Type 2 diabetes has accounted for highest market share due to increasing disposable income and rising prevalence of obesity. Increasing physical inactivity created demand for the diabetes drugs. Type 1 diabetes held the second large market share in 2016 owing to increasing environmental damage all over the world that is contributing to the rising prevalence of type 1 diabetes. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are anticipated to grow during the forecast period 2017 to 2025 due to the high prevalence of diabetes in the relatives and heredity reason.
Different types of distribution channels are present in the diabetes drugs market those are Hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies captured highest market share in 2016, owing to the availability of trained & qualified personnel and favorable reimbursement structure. The online pharmacies is estimated to register highest CAGR in the forecast period, which is attributed to the technological adaptation and acceptance of online pharmacies by population. The retail pharmacies showed the moderate market share in 2016 owing to rising geriatric population & improvements in the healthcare facilities in developing countries are anticipated to propel the popularity of retail pharmacies during the forecast period. However, uncertain reimbursement scenarios across the world are attributed to restrain the diabetes drugs market to some extent during the forecast period.
Global Diabetes Drugs Market: Regional Segmentation
Geographically, the diabetes drugs Market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).
Global Diabetes Drugs Market: Competitive Landscape
The report also profiles major players in the Diabetes drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.
Diabetes Drugs Market has been segmented as given below:
Diabetes Drugs Market, by Therapy
- Glucagon-like peptide-1 (GLP-1) agonist
- Dipeptidyl-peptidase-4 (DPP-4) inhibitors
- Sodium glucose co-transporter 2 (SGLT2) inhibitors
Diabetes Drugs Market, by Disease Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Impaired Glucose Tolerance and Impaired Fasting Glycaemia
Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Diabetes Drugs Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- Latin America
- Rest of Latin America